Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 176949, 10 pages
http://dx.doi.org/10.1155/2015/176949
Clinical Study

Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes

1Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
2Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan 333, Taiwan
3Department of Biotechnology, Ming Chuan University, Taoyuan 333, Taiwan
4Genomic Medicine Research Core Laboratory, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan

Received 26 September 2014; Revised 22 December 2014; Accepted 5 January 2015

Academic Editor: Daisuke Koya

Copyright © 2015 Chia-Hung Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. L. Baggio and D. J. Drucker, “Biology of incretins: GLP-1 and GIP,” Gastroenterology, vol. 132, no. 6, pp. 2131–2157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. J. Holst, M. Bersani, A. H. Johnsen, H. Kofod, B. Hartmann, and C. Ørskov, “Proglucagon processing in porcine and human pancreas,” The Journal of Biological Chemistry, vol. 269, no. 29, pp. 18827–18833, 1994. View at Google Scholar · View at Scopus
  3. D. J. Drucker and M. A. Nauck, “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes,” The Lancet, vol. 368, no. 9548, pp. 1696–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. M. Egan, A. R. Clocquet, and D. Elahi, “The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes,” The Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 3, pp. 1282–1290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. S. L. Anderson, J. M. Trujillo, M. McDermott, and J. J. Saseen, “Determining predictors of response to exenatide in type 2 diabetes,” Journal of the American Pharmacists Association, vol. 52, no. 4, pp. 466–471, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Müssig, H. Staiger, F. Machicao et al., “Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion,” Diabetes, vol. 58, no. 7, pp. 1715–1720, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. S. A. Schäfer, K. Müssig, H. Staiger et al., “A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion,” Diabetologia, vol. 52, no. 6, pp. 1075–1082, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. A. Schäfer, O. Tschritter, F. Machicao et al., “Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms,” Diabetologia, vol. 50, no. 12, pp. 2443–2450, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Smushkin, M. Sathananthan, A. Sathananthan et al., “Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1,” Diabetes, vol. 61, no. 5, pp. 1082–1089, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. H.-C. Fehmann, J. Jiang, J. Schweinfurth et al., “Ligand-specificity of the rat GLP-I receptor recombinantly expressed in Chinese hamster ovary (CHO-) cells,” Zeitschrift fur Gastroenterologie, vol. 32, no. 4, pp. 203–207, 1994. View at Google Scholar · View at Scopus
  11. A. Kirkpatrick, J. Heo, R. Abrol, and W. A. Goddard III, “Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 49, pp. 19988–19993, 2012. View at Publisher · View at Google Scholar
  12. M. Beinborn, C. I. Worrall, E. W. McBride, and A. S. Kopin, “A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness,” Regulatory Peptides, vol. 130, no. 1-2, pp. 1–6, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Woodcock and L. J. Lesko, “Pharmacogenetics—tailoring treatment for the outliers,” The New England Journal of Medicine, vol. 360, no. 8, pp. 811–813, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Sathananthan, C. D. Man, F. Micheletto et al., “Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study,” Diabetes Care, vol. 33, no. 9, pp. 2074–2076, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. B. W. Bode, “Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections,” Clinical Therapeutics, vol. 29, supplement D, pp. S135–S144, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Matsuda and R. A. DeFronzo, “Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp,” Diabetes Care, vol. 22, no. 9, pp. 1462–1470, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Publisher · View at Google Scholar · View at Scopus
  18. B. W. Bode, W. V. Tamborlane, and P. C. Davidson, “Insulin pump therapy in the 21st century: strategies for successful use in adults, adolescents, and children with diabetes,” Postgraduate Medicine, vol. 111, no. 5, pp. 69–77, 2002. View at Google Scholar · View at Scopus
  19. C.-H. Lin, C.-H. Huang, J.-S. Tsai et al., “Effects of a novel short-term continuous subcutaneous insulin infusion program evaluated by continuous glucose monitoring on young adult type 1 diabetic patients in Taiwan,” Endocrine Journal, vol. 58, no. 10, pp. 835–840, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Tokuyama, K. Matsui, T. Egashira, O. Nozaki, T. Ishizuka, and A. Kanatsuka, “Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population,” Diabetes Research and Clinical Practice, vol. 66, no. 1, pp. 63–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. C.-T. Chang, C.-N. Tsai, C. Y. Tang et al., “Mixed sequence reader: a program for analyzing DNA sequences with heterozygous base calling,” The Scientific World Journal, vol. 2012, Article ID 365104, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Arnolds, S. Dellweg, J. Clair et al., “Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study,” Diabetes Care, vol. 33, no. 7, pp. 1509–1515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. B. Buse, R. M. Bergenstal, L. C. Glass et al., “Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial,” Annals of Internal Medicine, vol. 154, no. 2, pp. 103–112, 2011. View at Publisher · View at Google Scholar
  24. S. N. Davis, D. Johns, D. Maggs, H. Xu, J. H. Northrup, and R. G. Brodows, “Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents,” Diabetes Care, vol. 30, no. 11, pp. 2767–2772, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Koole, D. Wootten, J. Simms et al., “Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation,” Molecular Pharmacology, vol. 80, no. 3, pp. 486–497, 2011. View at Publisher · View at Google Scholar
  26. K. Pilgaard, C. B. Jensen, J. H. Schou et al., “The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men,” Diabetologia, vol. 52, no. 7, pp. 1298–1307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. E. Doyle, M. J. Theodorakis, H. W. Holloway, M. Bernier, N. H. Greig, and J. M. Egan, “The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity,” Regulatory Peptides, vol. 114, no. 2-3, pp. 153–158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. M. E. Doyle, N. H. Greig, H. W. Holloway, J. A. Betkey, M. Bernier, and J. M. Egan, “Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent,” Endocrinology, vol. 142, no. 10, pp. 4462–4468, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. Moon, H. Y. Kim, S. Park et al., “Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation,” The Journal of Biological Chemistry, vol. 287, no. 6, pp. 3873–3884, 2012. View at Publisher · View at Google Scholar · View at Scopus